GlassScriptPhysician profile
Ramachandra P Reddy
NPI 1689037616
$889.86
in general payments reported to CMS, 2019-2025
8 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $607 · 2024: $112 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $535 · Food and Beverage: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $534.87 |
| Food and Beverage | $354.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $534.87 | 2023 | Impella |
| Novartis Pharmaceuticals Corporation | $163.66 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.39 | 2024-2025 | Ninlaro |
| Octapharma USA, INC. | $34.21 | 2024 | Balfaxar |
| Astrazeneca Pharmaceuticals LP | $33.74 | 2025 | Tagrisso |
| Celgene Corporation | $27.46 | 2023 | Reblozyl |
| Sumitomo Pharma America, INC. | $21.75 | 2024 | Orgovyx |
| Eisai INC. | $18.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramachandra Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.